Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapy.
Hemminki O, Parviainen S, Juhila J, Turkki R, Linder N, Lundin J, Kankainen M, Ristimäki A, Koski A, Liikanen I, Oksanen M, Nettelbeck DM, Kairemo K, Partanen K, Joensuu T, Kanerva A, Hemminki A.
Hemminki O, et al. Among authors: kairemo k.
Oncotarget. 2015 Feb 28;6(6):4467-81. doi: 10.18632/oncotarget.2901.
Oncotarget. 2015.
PMID: 25714011
Free PMC article.
Clinical Trial.